LENOVO
15.8.2022 03:01:13 CEST | Business Wire | Press release
Today marks the first day of operation for Lenovo PCCW Solutions Limited1 , the new strategic partnership between Lenovo Group (HKSE: 992) (ADR: LNVGY) and PCCW (HKSE: 0008) set to capitalize on the estimated US$320 billion Asia IT services market.
The new company provides one-stop customer solutions that integrate IT services, devices, and digital infrastructure, and empowers clients to transform their businesses and operations with technology – from managing complex integrations to enhancing competitiveness with innovative applications.
Through the partnership, the company benefits from Lenovo’s global footprint in more than 180 markets, broad portfolio of end-to-end solutions, solid pedigree in innovation, and strong go-to-market and delivery capabilities.
Ken Wong, Executive Vice President of Lenovo and President of Lenovo Solutions and Services Group, said , “The partnership marks an important milestone in Lenovo’s service-led transformation journey since the formation of our Solutions and Services Group, as it bolsters the company’s capabilities to drive leadership in IT solutions. The synergy of capabilities and talents across the two organizations will help the new company grow in reach and competitiveness in markets across the Asia Pacific region.”
PCCW Solutions has been ranked number one in Systems Integration and Custom Application Development in Hong Kong SAR by IDC for eight consecutive years since 20142 . The new company builds upon PCCW Solutions’ track record as one of the region’s leading IT services providers. The 4,000-strong IT professionals will continue to partner closely with our customers to help them succeed in a more complex and rapidly evolving technology landscape.
Jerry Li, CEO of Lenovo PCCW Solutions, said , “This strategic partnership is a unique opportunity to accelerate the growth of our IT solutions business in the region. The new company, Lenovo PCCW Solutions, enables our customers to call upon a diverse wealth of skills, expertise, and go-to-market capabilities across Lenovo Solutions and Services Group. We are excited to embark on this growth journey, which enables us to expand our skillset, footprint, and solutions portfolio. With the combined strengths of our highly skilled talent, we look forward to contributing further to smart city development in the region.”
Market data estimates the Asia IT services market to be worth approximately US$320 billion in 2022, with expected growth at a CAGR of more than 10% to exceed US$470 billion by 2026. Lenovo PCCW Solutions is uniquely positioned to capture the growth opportunities in the market.
About Lenovo PCCW Solutions Limited
Lenovo PCCW Solutions is a leading technology solutions powerhouse in Asia Pacific. A strategic partnership formed between Lenovo and PCCW in August 2022, the company offers market-leading solutions to help organizations transform their operations, increase competitiveness, and enhance innovation through technology. Its wide range of technology solutions and service offerings include system integration, application development and operation, IT outsourcing, managed services, digital solutions, and technical services. To find out more about Lenovo PCCW Solutions, please visit www.pccwsolutions.com .
1 The company was previously referred to as “PCCW Lenovo Technology Solutions” in the 14 June 2022 filing with Hong Kong Stock Exchange. https://news.lenovo.com/pressroom/press-releases/lenovo-and-pccw-partnership/
2 https://www.pccwsolutions.com/site/en/news-entry/20220518/
View source version on businesswire.com: https://www.businesswire.com/news/home/20220811005363/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom